Off-Label Use of Biologic Agents in the Treatment of Dermatosis, Part 2: Etanercept, Efalizumab, Alefacept, Rituximab, Daclizumab, Basiliximab, Omalizumab, and Cetuximab

Statistics

Review article

Uso de Fármacos Biológicos en Dermatosis Fuera de la Indicación Aprobada. Segunda Parte: Etanercept, Efalizumab, Alefacept, Rituximab, Daclizumab, Basiliximab, Omalizumab y Cetuximab

G. Guhl

Corresponding author

guhl@aedv.es

Correspondence: Servicio de Dermatología, Hospital Universitario de la Princesa, Diego de León, 62, 28006 Madrid, Spain.

, B. Díaz-Ley, J. Fernández-Herrera

Servicio de Dermatología, Hospital Universitario de la Princesa, Madrid, Spain

Read

9205

Times
was read the article

3764

Total PDF

5441

Total HTML

Share statistics

Article information

ISSN: 15782190
Original language: English

DOI:10.1016/S1578-2190(08)70191-4

The statistics are updated each day

Year/Month	Html	Pdf	Total

2025 6	104	34	138
2025 5	153	27	180
2025 4	134	20	154
2025 3	105	20	125
2025 2	102	35	137
2025 1	72	39	111
2024 12	65	29	94
2024 11	86	58	144
2024 10	68	65	133
2024 9	80	32	112
2024 8	92	76	168
2024 7	70	36	106
2024 6	80	37	117
2024 5	79	48	127
2024 4	69	37	106
2024 3	92	52	144
2024 2	59	33	92
2024 1	47	42	89
2023 12	62	30	92
2023 11	44	42	86
2023 10	34	21	55
2023 9	53	37	90
2023 8	25	39	64
2023 7	37	57	94
2023 6	52	36	88
2023 5	37	34	71
2023 4	23	22	45
2023 3	29	19	48
2023 2	31	20	51
2023 1	45	28	73
2022 12	46	38	84
2022 11	22	30	52
2022 10	36	22	58
2022 9	26	28	54
2022 8	50	52	102
2022 7	24	31	55
2022 6	22	38	60
2022 5	41	57	98
2022 4	49	40	89
2022 3	55	59	114
2022 2	58	23	81
2022 1	65	42	107
2021 12	62	40	102
2021 11	41	39	80
2021 10	33	47	80
2021 9	40	40	80
2021 8	34	33	67
2021 7	29	29	58
2021 6	22	31	53
2021 5	31	31	62
2021 4	94	74	168
2021 3	67	27	94
2021 2	50	34	84
2021 1	47	20	67
2020 12	27	21	48
2020 11	36	24	60
2020 10	28	9	37
2020 9	31	14	45
2020 8	24	27	51
2020 7	33	7	40
2020 6	27	29	56
2020 5	25	28	53
2020 4	26	18	44
2020 3	33	27	60
2020 2	5	8	13
2020 1	0	5	5
2019 12	0	10	10
2019 11	0	9	9
2019 10	0	13	13
2019 9	0	18	18
2019 8	0	8	8
2019 7	0	16	16
2019 6	0	17	17
2019 5	1	65	66
2019 4	0	25	25
2019 3	0	14	14
2019 2	0	17	17
2019 1	0	8	8
2018 12	0	8	8
2018 4	0	4	4
2018 3	0	5	5
2018 2	13	11	24
2018 1	25	14	39
2017 12	28	22	50
2017 11	19	11	30
2017 10	22	16	38
2017 9	27	21	48
2017 8	39	8	47
2017 7	39	13	52
2017 6	51	32	83
2017 5	51	18	69
2017 4	43	14	57
2017 3	46	40	86
2017 2	29	17	46
2017 1	27	23	50
2016 12	46	15	61
2016 11	44	17	61
2016 10	43	25	68
2016 9	50	14	64
2016 8	46	17	63
2016 7	62	23	85
2016 6	19	12	31
2016 5	10	23	33
2016 4	7	1	8
2016 3	5	7	12
2016 2	13	1	14
2016 1	15	9	24
2015 12	12	9	21
2015 11	14	13	27
2015 10	9	3	12
2015 9	9	6	15
2015 8	7	5	12
2015 7	25	16	41
2015 6	44	23	67
2015 5	89	34	123
2015 4	41	35	76
2015 3	52	13	65
2015 2	28	25	53
2015 1	46	24	70
2014 12	38	24	62
2014 11	33	20	53
2014 10	41	20	61
2014 9	42	33	75
2014 8	40	23	63
2014 7	52	27	79
2014 6	38	12	50
2014 5	49	16	65
2014 4	48	14	62
2014 3	35	22	57
2014 2	30	28	58
2014 1	25	28	53
2013 12	41	29	70
2013 11	34	20	54
2013 10	31	31	62
2013 9	29	38	67
2013 8	28	30	58
2013 7	33	47	80
2013 6	23	66	89
2013 5	45	43	88
2013 4	30	53	83
2013 3	40	26	66
2013 2	53	17	70
2013 1	19	3	22

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter